Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial
Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial
Jean‐Eudes Dazard, Anas Fares, Robert D. Brook, Sanjay Rajagopalan et al.
Citations
13 citations
Journal
Circulation
Topics
Hormonal Regulation and Hypertension
Field-Weighted Citation Impact (FWCI)
4.65
article
Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial
Jean‐Eudes Dazard, Anas Fares, Robert D. Brook, Sanjay Rajagopalan, Matthew R. Weir, Sadeer G Al-Kindi, Cheryl Cameron, Michael E. Farkouh, Armando Vergara-Martel, Kim A. Connelly, Mirela Dobre, Laleh Razavi-Nematollahi, Mark J. Cameron, Heather Conger, Juan Gaztañaga, Jonnelle M. Edwards, Gabriel Tensol Rodrigues Pereira, Ann M. Dever, Bertram Pitt
article en
13 citations
Abstract
No abstract available for this paper.
Publication Tag
CirculationVol. 150(9)
Institutions
University of Maryland, Baltimore (US), Winthrop-University Hospital (US), Houston Methodist (US), St. Michael's Hospital (CA), University of Maryland Medical Center (US), Wayne State University (US), University Hospitals of Cleveland (US), Michigan Medicine (US), Sinai Health System (US), Case Western Reserve University (US)
Funders
National Institutes of Health, National Heart, Lung, and Blood Institute